 |
|
UT scientists discover link between protein and lung disease
September 16, 2009In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD). Findings appear online and will be in the January 2010 print issue of The FASEB Journal, the journal of The Federation of American Societies for Experimental Biology.
More than 12 million Americans are currently diagnosed with this incurable illness, which is the fourth leading cause of death, the National Heart Lung and Blood Institute reports. In the United States, the term COPD includes two main conditions - emphysema and chronic obstructive bronchitis.
The researchers were able to prevent COPD features in a mouse model by genetically removing osteopontin. To gauge the applicability of their findings to humans, the investigators analyzed the airways of people with COPD and found elevated levels of the protein.
"This is an important crossover study," said Michael Blackburn, Ph.D., the study's senior author and professor in the Department of Biochemistry and Molecular Biology at The University of Texas Medical School at Houston. "Because we can show osteopontin is elevated in people with COPD, this suggests that osteopontin could serve as both an indicator of disease progression and a therapeutic target."
In the study, researchers induced COPD features in mice and then compared symptoms experienced by mice with osteopontin and those without. The mice without the protein had less inflammation and lung disease. "The lack of osteopontin in the mice prevented the COPD features," said Daniel Schneider, the study's lead author and an M.D./Ph.D. candidate at the UT Health Science Center at Houston.
"This paper reveals exciting new information on the pathogenetic mechanisms involved in the development of chronic obstructive pulmonary disease and emphysema," said Richard J. Castriotta, M.D., professor and director of the Pulmonary, Critical Care and Sleep Medicine Division at the UT Medical School at Houston and medical director of the Sleep Disorder Center at Memorial Hermann - Texas Medical Center.
The study stems from research in Blackburn's laboratory involving a signaling molecule named adenosine, which can orchestrate the process of inflammation in wound healing. Adenosine can also activate a cell surface receptor associated with COPD named A2B and produce osteopontin.
Blackburn's decade-long research has focused on blocking the A2B receptor. With the new study linking osteopontin to COPD, Blackburn believes his laboratory may have uncovered a protein that could lead to a more targeted approach to treating emphysema.
"As a physician scientist, one goal of drug development is to offer more specific drug targets to treat the disorder and osteopontin provides a specific target that may be associated with fewer side effects," Schneider said.
"This paper adds a new element, osteopontin, to the mix by discovering its significant role in the development of COPD with emphysema ... It's still too early to be used clinically, but there may be a place for osteopontin in the future as an indicator of lung disease in progress that leads to COPD and emphysema," Castriotta said.
Blackburn is director of the Graduate Program in Biochemistry and Molecular Biology at the UT Medical School.
Schneider is a graduate research assistant at The University of Texas Graduate School of Biomedical Sciences at Houston and is a recipient of a T32 training grant by the Center for Clinical and Translational Sciences at the UT Health Science Center at Houston.
The study is titled "Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease." Other contributors from the Department of Biochemistry and Molecular Biology were graduate students Janci C. Lindsay and Yang Zhou, as well as senior research assistant Jose G. Molina.
The study was funded by the National Institutes of Health and the National Center for Research Resources.
The University of Texas Health Science Center at Houston
"This is an important crossover study," said Michael Blackburn, Ph.D., the study's senior author and professor in the Department of Biochemistry and Molecular Biology at The University of Texas Medical School at Houston. "Because we can show osteopontin is elevated in people with COPD, this suggests that osteopontin could serve as both an indicator of disease progression and a therapeutic target."
In the study, researchers induced COPD features in mice and then compared symptoms experienced by mice with osteopontin and those without. The mice without the protein had less inflammation and lung disease. "The lack of osteopontin in the mice prevented the COPD features," said Daniel Schneider, the study's lead author and an M.D./Ph.D. candidate at the UT Health Science Center at Houston.
"This paper reveals exciting new information on the pathogenetic mechanisms involved in the development of chronic obstructive pulmonary disease and emphysema," said Richard J. Castriotta, M.D., professor and director of the Pulmonary, Critical Care and Sleep Medicine Division at the UT Medical School at Houston and medical director of the Sleep Disorder Center at Memorial Hermann - Texas Medical Center.
The study stems from research in Blackburn's laboratory involving a signaling molecule named adenosine, which can orchestrate the process of inflammation in wound healing. Adenosine can also activate a cell surface receptor associated with COPD named A2B and produce osteopontin.
Blackburn's decade-long research has focused on blocking the A2B receptor. With the new study linking osteopontin to COPD, Blackburn believes his laboratory may have uncovered a protein that could lead to a more targeted approach to treating emphysema.
"As a physician scientist, one goal of drug development is to offer more specific drug targets to treat the disorder and osteopontin provides a specific target that may be associated with fewer side effects," Schneider said.
"This paper adds a new element, osteopontin, to the mix by discovering its significant role in the development of COPD with emphysema ... It's still too early to be used clinically, but there may be a place for osteopontin in the future as an indicator of lung disease in progress that leads to COPD and emphysema," Castriotta said.
Blackburn is director of the Graduate Program in Biochemistry and Molecular Biology at the UT Medical School.
Schneider is a graduate research assistant at The University of Texas Graduate School of Biomedical Sciences at Houston and is a recipient of a T32 training grant by the Center for Clinical and Translational Sciences at the UT Health Science Center at Houston.
The study is titled "Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease." Other contributors from the Department of Biochemistry and Molecular Biology were graduate students Janci C. Lindsay and Yang Zhou, as well as senior research assistant Jose G. Molina.
The study was funded by the National Institutes of Health and the National Center for Research Resources.
The University of Texas Health Science Center at Houston
Osteopontin Current Events and Osteopontin News RSSSmoking increases potential for metastatic pancreatic cancer
Smoking has once again been implicated in the development of advanced cancer. Exposure to nicotine by way of cigarette smoking may increase the likelihood that pancreatic ductal adenocarcinoma will become metastatic.
New mediator of smoking recruits
Current research suggests that smoking increases the production of osteopontin in the lungs, which contributes to the development of smoking-related lung disease.
Skin care: new research into scar-free healing
New research from the University of Bristol shows that by suppressing one of the genes that normally switches on in wound cells, wounds can heal faster and reduce scarring. This has major implications not just for wound victims but also for people who suffer organ tissue damage through illness or abdominal surgery.
Biomarker May Be an Early Predictor of Advanced Breast Cancer
Researchers have identified a molecule that may be more accurate than existing biological signposts used to predict which breast cancers will develop into advanced forms of the disease.
Mice stressed in simulated weightlessness show organ atrophy
A ground-based, experimental model used to simulate astronaut weightlessness in space has provided Rutgers scientists an opportunity to study the effects of stress on immune organs.
Study identifies key player in the body's immune response to chronic stress
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Molecule linked to autoimmune disease relapses identified at Stanford
The ebb and flow of such autoimmune diseases as multiple sclerosis, lupus and rheumatoid arthritis has long been a perplexing mystery.
Scientists discover new gene responsible for spread of cancer
Scientists at the University of Liverpool have identified a new gene that causes the spread of cancer.
Advanced genomics and proteomics improve the diagnosis and treatment of a deadly lung disease
In an article in the Jan. 15 issue of the American Journal of Respiratory Critical Care Medicine, University of Pittsburgh researchers report that a serious, life-threatening form of pulmonary fibrosis, called idiopathic pulmonary fibrosis, lacks all the hallmarks of inflammation and is probably unnecessarily treated with anti-inflammatory drugs.
Elevated blood levels of a protein are linked to asbestos-induced cancers
Researchers at New York University School of Medicine and Wayne State University have found a molecule that reveals the early stages of pleural mesothelioma, a chest cancer caused by asbestos.
More Osteopontin Current Events and Osteopontin News Articles
|
Osteopontin: Role in Cell Signalling and Adhesion (Annals of the New York Academy of Sciences) by William T. Butler (Author), David T. Denhardt (Author), David T. Denhardt (Editor), Ann F. Chambers (Editor) | |
![Genetic, biochemical and evolutionary facets of Xmrk-induced melanoma formation in the fish Xiphophorus [An article from: Comparative Biochemistry and Physiology, Part C]](http://ecx.images-amazon.com/images/I/51A51TBEEML._SL160_.jpg) |
Genetic, biochemical and evolutionary facets of Xmrk-induced melanoma formation in the fish Xiphophorus [An article from: Comparative Biochemistry and Physiology, Part C] by S. Meierjohann (Author), M. Schartl (Author), J.N. Volff (Author) This digital document is a journal article from Comparative Biochemistry and Physiology, Part C, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Certain interspecific hybrids of the fish Xiphophorus spontaneously develop melanoma induced by the derepression of the Xmrk oncogene. Xmrk is a recent duplicate of an orthologue of the mammalian epidermal growth factor receptor gene Egfr. In addition to a specific overexpression in melanoma, amino-acid substitutions in the extracellular domain leading to ligand-independent dimerisation and constitutive autophosphorylation are responsible for the tumorigenic potential of Xmrk. The Xmrk... |
| © 2009 BrightSurf.com |